Protalix BioTherapeutics Issues 2025 Letter to Stockholders

Stock Information for Protalix BioTherapeutics Inc. (DE)

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Protalix BioTherapeutics Inc. (DE)

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa
Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results
Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024
Protalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
Kaskela Law LLC Announces Shareholder Investigation of Protalix BioTherapeutics, Inc. (NYSE: PLX) and Encourages Investors to Contact the Firm
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
Protalix BioTherapeutics to Present at the Life Sciences Investor Forum September 19, 2024

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.